If you are looking for Laurus Labs Ltd share price targets for the years 2023 to 2030, we will mention them below. Laurus Labs Limited was listed on both the NSE and BSE exchanges in India. The company has shown strong performance over the few years and has increased in share price since its Initial Public Offering (IPO) in 2016.
Before predicting its share price, we should know the complete information about the company. As what kind of production and the sectors in which the company operates. Also, whether there any growth scope or not in the future?
Laurus Labs Limited is a pharmaceutical company that engages in research, development and APIs. The company specializes in manufacturing pharmaceutical ingredients (APIs) used for HIV/AIDS, Hepatitis C and Oncology treatments.
The company work with all the top 10 generic pharmaceutical companies in the world and also sells APIs in 56 countries. It has three different business units namely Generic API, Generic FDF and Synthesis. Furthermore, the company has commercialized more than 60 products.
The company reported that the revenue has been increasing over the years and has earned a total revenue of Rs 1,545 crore in FY22. If we compare it with the previous year, it was an increase of 50.16%↑.
The net income is Rs 203.04 crore which is an increase of 32.05% over the previous year. But the Net Profit Margin is 13.14% which has decreased by around 12.05%↓ and the trend shows downward.
Fundamentals of Laurus Lab Limited
| Company Name | Laurus Labs Limited |
| Industry | Pharmaceutical |
| Country | India |
| Founded | 2005 |
| Primary Exchange | NSE/BSE |
| Traded Volume | 648,058.00 |
| Market Cap | ₹ 16,848 Cr |
| Revenue | ₹ 1,545 Cr |
| Net Income | ₹ 203.04 Cr |
| Net Profit Margin | 13.14% |
| EPS (TTM) | 17.02 |
| PE Ratio (TTM) | 17.91 |
| Industry PE | 25.05 |
| ROE | 27.82 |
| Dividend Yield | 0.66 |
| Debt to Equity | 0.56 |
| 52 Week Low | 298.50 |
| 52 Week High | 626.30 |
| Buy / Sell / Hold | Hold |
| Face Value | 2 |
| Official Website | www.lauruslabs.com |
Laurus Labs share price history – Last 5 years
| Year | Low | High |
|---|---|---|
| 2018 | 68.17 | 107.57 |
| 2019 | 66.69 | 74.87 |
| 2020 | 64.96 | 353.15 |
| 2021 | 350.15 | 688.85 |
| 2022 | 464.70 | 590.10 |
| 2023 | 305.20 | —? |
Shareholding pattern
| Promoters | 27.22% |
| Foreign Institutions | 21.88% |
| Domestic Instituttions | 3.92% |
| Mutual Fund | 5.43% |
| Retail & Others | 41.52% |
Laurus Labs share price target for 2023, 2024, 2025 to 2030
Laurus Labs’ share price target is a prediction value of the share for the future. It is based on our research, history, fundamentals and industry trends. It has a downward trend in the market and is expected to perform well in long term.
Note: Readers are advised that the target share price forecast is based on our research, experience and technical analysis. So, the estimated future value may differ from the actual price. Therefore, you are advised to do your own research and consult with your financial advisor.
2023
In 2023, the minimum share price target will be Rs 255.20 to Rs 275.10 based on market trends and our research. And at the end of the year, the maximum target price for Laurus Labs shares will be Rs 280.40 to Rs 305.30.
2024
As per the market trends, research and forecasting system, the stock price is likely to decline in the next 12 months. And the maximum share price of Dabur India Limited could be Rs 255.20 to Rs 275.70 by 2024.
2025
In 2025, the minimum share price target will be Rs 315.50 to Rs 335.40 based on market trends and our research. And at the end of the year, the maximum target price for Lauras Labs shares will be Rs 350.30 to Rs 380.20.
2026
With the current market trends, history, research and technical analysis, Laurus Labs’ share price is likely to be downward in the next few months. The expected share price of Laurua Labs could be Rs 380.80 to Rs 435.10 by 2026.
2027
Based on the market trends, research and forecast system, the maximum share price of Laurus Labs could be Rs 455.30 to Rs 475.20 by 2027.
2028
In 2028, the minimum share price target will be Rs 480.90 to Rs 495.50 based on market trends and our research. And at the end of the year, the maximum target price for Laurus Labs shares will be Rs 485.30 to Rs 525.40.
2029
As per the current market trends, research and technical analysis, Laurus Labs share price is likely to remain positive in the next few months. While it is not possible to estimate the exact price. Nevertheless, the estimated Laurus Labs share price could be in the range of Rs 540.20 to Rs 565.30 by 2029.
2030
In 2030, the minimum share price target will be Rs 550.50 to Rs 580.20 based on market trends and our research. And at the end of the year, the maximum target price for Laurus shares will be Rs 610.50 to Rs 635.70.
Risk factors
The company has a few risk factors and has good future growth prospects. The company has established unwavering trust with the top 10 generic pharmaceutical companies in the world. Still, the stock market is volatile and changes in the following conditions can affect the stock price of the company.
- Govt. Policies: Sometimes the government changes its financial laws, which can affect any company.
- Market Trend: There are many reasons in the world that can affect share prices.
- Competition in the Market: The entry of any new company may affect its market share in the world.
- Global Crisis: Global crisis comes in various ways in the world. Of course, it can destroy the economic structure.
FAQs
A; The target share price of Laurus Labs will Rs Rs 350.30 to Rs 380.20 in 2025.
A: The target share price of Laurus Labs will be Rs 485.30 to Rs 525.40.in 2028.
A: The target share price of Laurus Labs will be Rs 610.50 to Rs 635.70 in 2030.
A: You can buy Laurus Labs shares by opening a Demat account.
Disclaimer: The share price targets on our website (bankshala.com) are for general information only. We are not SEBI-registered financial advisors and no part of the website content provided by us should be considered financial advice. Before investing in any company you should do your own research, analyze and consult your financial advisor before taking any decision.
